anti-GPC1 CAR T-cell therapy (Keio University School of Medicine)

N/A

Report date: 2025/03/14 16:28:51

Base Information

Drug Nameanti-GPC1 CAR T-cell therapy (Keio University School of Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionGlypican-1 modulators

TargetsGlypican-1

Therapy Area/IndicationsSolid tumoursCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKeio University

China Registration ClassN/A

Develop Information

Active CompaniesKeio University

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Squamous Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A